Novavax, Inc. (NVV1.F)
EUR 8.74
(0.66%)
EUR 8.74
(0.66%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 556.38 Million USD | -65.2% |
| 2022 | 1.59 Billion USD | 39.49% |
| 2021 | 1.14 Billion USD | 141.02% |
| 2020 | 475.59 Million USD | 2448.48% |
| 2019 | 18.66 Million USD | -45.57% |
| 2018 | 34.28 Million USD | 9.98% |
| 2017 | 31.17 Million USD | 103.06% |
| 2016 | 15.35 Million USD | -57.65% |
| 2015 | 36.25 Million USD | 18.24% |
| 2014 | 30.65 Million USD | 46.59% |
| 2013 | 20.91 Million USD | -5.26% |
| 2012 | 22.07 Million USD | 50.3% |
| 2011 | 14.68 Million USD | 4182.22% |
| 2010 | 343 Thousand USD | 5.54% |
| 2009 | 325 Thousand USD | -69.45% |
| 2008 | 1.06 Million USD | -29.68% |
| 2007 | 1.51 Million USD | -67.69% |
| 2006 | 4.68 Million USD | -36.61% |
| 2005 | 7.38 Million USD | -10.56% |
| 2004 | 8.26 Million USD | -29.91% |
| 2003 | 11.78 Million USD | -21.46% |
| 2002 | 15 Million USD | -37.65% |
| 2001 | 24.06 Million USD | 872.36% |
| 2000 | 2.47 Million USD | 106.25% |
| 1999 | 1.2 Million USD | 71.43% |
| 1998 | 700 Thousand USD | 40.0% |
| 1997 | 500 Thousand USD | 400.0% |
| 1996 | 100 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 415.48 Million USD | 342.69% |
| 2024 Q1 | 93.85 Million USD | -62.96% |
| 2023 Q4 | 253.39 Million USD | 1048.47% |
| 2023 Q3 | 22.06 Million USD | -94.8% |
| 2023 Q2 | 424.42 Million USD | 6702.77% |
| 2023 Q1 | -6.42 Million USD | -102.23% |
| 2023 FY | 556.38 Million USD | -65.2% |
| 2022 Q3 | 734.57 Million USD | 295.09% |
| 2022 FY | 1.59 Billion USD | 39.49% |
| 2022 Q1 | 703.97 Million USD | 216.82% |
| 2022 Q2 | 185.92 Million USD | -73.59% |
| 2022 Q4 | 287.82 Million USD | -60.82% |
| 2021 Q1 | 447.22 Million USD | 59.92% |
| 2021 Q3 | 178.84 Million USD | -39.99% |
| 2021 Q2 | 298.01 Million USD | -33.36% |
| 2021 FY | 1.14 Billion USD | 141.02% |
| 2021 Q4 | 222.2 Million USD | 24.24% |
| 2020 FY | 475.59 Million USD | 2448.48% |
| 2020 Q2 | 35.53 Million USD | 952.35% |
| 2020 Q3 | 157.02 Million USD | 341.85% |
| 2020 Q4 | 279.65 Million USD | 78.1% |
| 2020 Q1 | 3.37 Million USD | -61.69% |
| 2019 Q2 | 3.35 Million USD | -15.7% |
| 2019 FY | 18.66 Million USD | -45.57% |
| 2019 Q4 | 8.81 Million USD | 251.66% |
| 2019 Q1 | 3.98 Million USD | -35.01% |
| 2019 Q3 | 2.5 Million USD | -25.32% |
| 2018 FY | 34.28 Million USD | 9.98% |
| 2018 Q4 | 6.12 Million USD | -20.79% |
| 2018 Q3 | 7.73 Million USD | -28.2% |
| 2018 Q2 | 10.77 Million USD | 11.6% |
| 2018 Q1 | 9.65 Million USD | -7.29% |
| 2017 Q4 | 10.41 Million USD | 24.66% |
| 2017 Q1 | 5.68 Million USD | 5.2% |
| 2017 FY | 31.17 Million USD | 103.06% |
| 2017 Q2 | 6.73 Million USD | 18.52% |
| 2017 Q3 | 8.35 Million USD | 24.06% |
| 2016 FY | 15.35 Million USD | -57.65% |
| 2016 Q3 | 3.23 Million USD | 28.98% |
| 2016 Q2 | 2.5 Million USD | -40.61% |
| 2016 Q4 | 5.39 Million USD | 67.1% |
| 2016 Q1 | 4.21 Million USD | -27.93% |
| 2015 Q2 | 13.99 Million USD | 41.7% |
| 2015 FY | 36.25 Million USD | 18.24% |
| 2015 Q4 | 5.85 Million USD | -10.3% |
| 2015 Q1 | 9.87 Million USD | 46.89% |
| 2015 Q3 | 6.52 Million USD | -53.38% |
| 2014 Q2 | 8.25 Million USD | 10.68% |
| 2014 Q3 | 8.21 Million USD | -0.54% |
| 2014 FY | 30.65 Million USD | 46.59% |
| 2014 Q4 | 6.72 Million USD | -18.14% |
| 2014 Q1 | 7.46 Million USD | -14.7% |
| 2013 Q3 | 4.8 Million USD | 36.0% |
| 2013 FY | 20.91 Million USD | -5.26% |
| 2013 Q2 | 3.53 Million USD | -7.88% |
| 2013 Q1 | 3.83 Million USD | -16.05% |
| 2013 Q4 | 8.74 Million USD | 82.17% |
| 2012 FY | 22.07 Million USD | 50.3% |
| 2012 Q4 | 4.56 Million USD | -20.8% |
| 2012 Q2 | 7.1 Million USD | 53.02% |
| 2012 Q1 | 4.64 Million USD | -20.58% |
| 2012 Q3 | 5.76 Million USD | -18.84% |
| 2011 Q1 | 834 Thousand USD | 1535.29% |
| 2011 FY | 14.68 Million USD | 4182.22% |
| 2011 Q4 | 5.84 Million USD | 16.71% |
| 2011 Q3 | 5 Million USD | 66.88% |
| 2011 Q2 | 3 Million USD | 259.83% |
| 2010 Q3 | 175 Thousand USD | 2400.0% |
| 2010 Q2 | 7000.00 USD | -93.64% |
| 2010 Q4 | 51 Thousand USD | -70.86% |
| 2010 Q1 | 110 Thousand USD | 48.65% |
| 2010 FY | 343 Thousand USD | 5.54% |
| 2009 Q2 | 29 Thousand USD | 38.1% |
| 2009 Q1 | 21 Thousand USD | -70.0% |
| 2009 FY | 325 Thousand USD | -69.45% |
| 2009 Q4 | 74 Thousand USD | -63.18% |
| 2009 Q3 | 201 Thousand USD | 593.1% |
| 2008 Q2 | 342 Thousand USD | -25.33% |
| 2008 Q1 | 458 Thousand USD | 172.81% |
| 2008 FY | 1.06 Million USD | -29.68% |
| 2008 Q3 | 194 Thousand USD | -43.27% |
| 2008 Q4 | 70 Thousand USD | -63.92% |
| 2007 Q4 | -629 Thousand USD | -147.83% |
| 2007 Q3 | 1.31 Million USD | 732.28% |
| 2007 Q2 | 158 Thousand USD | -76.35% |
| 2007 Q1 | 668 Thousand USD | -50.45% |
| 2007 FY | 1.51 Million USD | -67.69% |
| 2006 Q1 | 1.3 Million USD | -41.93% |
| 2006 Q4 | 1.34 Million USD | 12.99% |
| 2006 FY | 4.68 Million USD | -36.61% |
| 2006 Q3 | 1.19 Million USD | 42.19% |
| 2006 Q2 | 839 Thousand USD | -35.61% |
| 2005 Q4 | 2.24 Million USD | 20.19% |
| 2005 FY | 7.38 Million USD | -10.56% |
| 2005 Q3 | 1.86 Million USD | -19.35% |
| 2005 Q2 | 2.31 Million USD | 140.64% |
| 2005 Q1 | 962 Thousand USD | -52.98% |
| 2004 Q4 | 2.04 Million USD | 213.32% |
| 2004 Q1 | 3.22 Million USD | -20.45% |
| 2004 FY | 8.26 Million USD | -29.91% |
| 2004 Q3 | 653 Thousand USD | -78.27% |
| 2004 Q2 | 3 Million USD | -6.68% |
| 2003 Q3 | 4.26 Million USD | 87.65% |
| 2003 FY | 11.78 Million USD | -21.46% |
| 2003 Q1 | 1.19 Million USD | -29.72% |
| 2003 Q2 | 2.27 Million USD | 90.54% |
| 2003 Q4 | 4.04 Million USD | -5.18% |
| 2002 Q3 | 2.46 Million USD | -48.01% |
| 2002 Q2 | 4.74 Million USD | -22.14% |
| 2002 Q4 | 1.69 Million USD | -31.13% |
| 2002 Q1 | 6.09 Million USD | -0.38% |
| 2002 FY | 15 Million USD | -37.65% |
| 2001 Q2 | 7.94 Million USD | 59.99% |
| 2001 Q1 | 4.96 Million USD | 515.37% |
| 2001 Q3 | 5.03 Million USD | -36.59% |
| 2001 FY | 24.06 Million USD | 872.36% |
| 2001 Q4 | 6.11 Million USD | 21.42% |
| 2000 Q2 | 588 Thousand USD | -17.18% |
| 2000 Q3 | 370 Thousand USD | -37.07% |
| 2000 Q4 | 807 Thousand USD | 118.11% |
| 2000 FY | 2.47 Million USD | 106.25% |
| 2000 Q1 | 710 Thousand USD | 1.43% |
| 1999 Q2 | 300 Thousand USD | 200.0% |
| 1999 Q4 | 700 Thousand USD | 600.0% |
| 1999 Q3 | 100 Thousand USD | -66.67% |
| 1999 Q1 | 100 Thousand USD | -50.0% |
| 1999 FY | 1.2 Million USD | 71.43% |
| 1998 Q2 | 100 Thousand USD | -50.0% |
| 1998 Q3 | 200 Thousand USD | 100.0% |
| 1998 Q4 | 200 Thousand USD | 0.0% |
| 1998 FY | 700 Thousand USD | 40.0% |
| 1998 Q1 | 200 Thousand USD | -33.33% |
| 1997 Q2 | 100 Thousand USD | 0.0% |
| 1997 Q3 | 100 Thousand USD | 0.0% |
| 1997 FY | 500 Thousand USD | 400.0% |
| 1997 Q4 | 300 Thousand USD | 200.0% |
| 1997 Q1 | 100 Thousand USD | 0.0% |
| 1996 Q3 | 100 Thousand USD | 0.0% |
| 1996 Q1 | 100 Thousand USD | 0.0% |
| 1996 Q4 | - USD | -100.0% |
| 1996 Q2 | 100 Thousand USD | 0.0% |
| 1996 FY | 100 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| BioNTech SE | 3.81 Billion EUR | 85.431% |
| CureVac N.V. | 53.75 Million EUR | -934.975% |
| Biotest Aktiengesellschaft | 684.6 Million EUR | 18.729% |
| Biotest Aktiengesellschaft | 684.6 Million EUR | 18.729% |
| BRAIN Biotech AG | 55.33 Million EUR | -905.479% |
| Formycon AG | 77.69 Million EUR | -616.101% |
| Heidelberg Pharma AG | 9.85 Million EUR | -5543.442% |
| Medigene AG | 6.03 Million EUR | -9120.782% |